April lives in Federal Way, Washington, and was diagnosed with Müllerian clear cell carcinoma. What has been your frustration in having a rare form of ovarian cancer? My biggest frustration is finding effective treatments and battling my insurance company to approve treatments. My insurance continues to deny treatments like immunotherapy, calling it investigational because there … Continued
Heather lives in Muskegon, and was diagnosed with small cell carcinoma, hypercalcemic type. What has been your frustration in having a rare form of ovarian cancer? My local doctors shoved it off as pregnancy symptoms or being a hypochondriac. I was “too young” to have ovarian cancer. I was having awful pain and vomiting while … Continued
Renee lives in Cadillac, and was diagnosed with carcinosarcoma. What has been your frustration in having a rare form of ovarian cancer? I became frustrated when I was not given much information from my gynecologic oncology team about my cancer. I had to resort to the internet to learn about it. Although my rare type … Continued
Jill lives in Bridgeport, Connecticut, and was diagnosed with grade 3, stage IVB squamous cell carcinoma. What has been your frustration in having a rare form of ovarian cancer? Relaying the severity of my diagnosis to family/friends is incredibly frustrating. I understand the need to focus on the positive, but realistically speaking, there are no … Continued
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still so much to report … research progress, a brand new clinical trial initiative, our upcoming Fall Advocacy Day, and the list goes on. Read on … Continued
B. Dana Kivel has a plea to the ovarian cancer community, to medical professionals, to the world: “See me. Listen to me. I’m one of the people, the tens of thousands of people who have metastatic ovarian cancer.” But while Dana has a gendered gynecologic cancer, their gender identity does not align with what one would … Continued
A recent study has shed more light on the demographics of hereditary ovarian cancer, and provides further data to suggest an urgent need for increased genetic counseling for potentially high-risk Black women, as well as increased genetic testing in Black ovarian cancer patients. The study, which took place over the course of 20 years and … Continued
November 15-16, 2021 | Register Today! Are you passionate about issues affecting the ovarian cancer community? Now is your chance to have your voice heard at the highest levels — without ever leaving home! OCRA’s Virtual Advocacy Day is a rare opportunity to communicate directly with your Members of Congress, and advocate for federal programs … Continued
At first glance, Jonathan Sockolosky and Andrew Berger, may seem like they have very little in common. Jonathan lives in San Francisco and is a scientist, while Andrew lives in New York, and works in the finance industry. Different as they appear, there is one thing that unites them: their connection to ovarian cancer. Both … Continued
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news outlets are describing as having found the “Achilles’ Heel” of ovarian cancer cells. This opens the door for new research in biomarkers and the development … Continued
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in some patients. This discovery may aid in the development of future ovarian cancer therapies, as it points to the potential effectiveness of a targeted inhibitor … Continued
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the standard of care treatments to rapidly test and deliver new therapies to patients with advanced ovarian cancer or recurrent … Continued
Get email updates about research news, action alerts, and ways to join the fight.
